Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 219-227

  Kolnagou, Annita ^a   Economides, Charalambos ^a   Eracleous, Eleni ^a   Kontoghiorghes, George ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Cardiomyopathy; Deferiprone (L1); Deferoxamine (DFO); Iron overload; Magnetic resonance imaging (MRI) T2 and T2*; Serum ferritin; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADULT; BLOOD TRANSFUSION; CARDIOMYOPATHY; CHELATION THERAPY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; INCIDENCE; IRON OVERLOAD; MAJOR CLINICAL STUDY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; RISK FACTOR; SIDEROSIS; THALASSEMIA;

ADMINISTRATION, ORAL; ADULT; ARRHYTHMIA; BLOOD TRANSFUSION; CARDIOMYOPATHIES; CHELATION THERAPY; COMBINED MODALITY THERAPY; DEFEROXAMINE; FALSE NEGATIVE REACTIONS; FEMALE; FERRITINS; HEART FAILURE, CONGESTIVE; HEMOSIDEROSIS; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; IRON CHELATING AGENTS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; PYRIDONES; RISK; SUBCUTANEOUS TISSUE; THALASSEMIA;

EID: 33745551087     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642542     Document Type: Conference Paper

References (20)

1. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chela tors for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(6):2161-2183.
2. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003; 26(8):553-584.
3. Kontoghiorghes GK, Jackson MI, Lunec J. In vitro screening of iron chelators using models of free radical damage. Free Rad Res Commun 1986; 2(2):115-124.
4. Halliwell B, Gutteridge JMC, Cross CE. Free radicals, antioxidants and human disease: where are we now? J Lab Clin Med 1992; 119(6):598-620.
5. Modell B, Berdoukas V. The Clinical Approach to Thalassaemia. London: Grune & Stratton, 1984.
6. Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultastruct Pathol 2000; 24(2):75-81.
7. Angellucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5):327-331.
8. Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE. Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 1995; 91(4):827-833.
9. Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kremastinos D. T2 relaxation time study of iron overload in β-thalassaemia. MAGMA 1998; 6(1):7-12.
10. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennel DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23):2171-2179.
11. Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia Br J Haematol 2004; 127(3):360-361.
12. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1Nll, and their combinations. Curr Med Chem 2005; 12(23:2663-2681.
13. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332):516-520.
14. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3):348-355.
15. Peng C-T, Chow K-C, Chen J-H, Chiang Y-P, Lin T-Y, Tsai C-H. Safety monitoring of cardiac and hepatic systems in β-thalassaemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6):392-397.
16. Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361(9352):184.
17. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK register. Lancet 2000; 355(9220):2051-2052.
18. Kolnagou A, Ioannou A, Kontos Ch, Economides Ch, Kontoghiorghes GJ. Effective high dose combination of deferiprone (L1) and deferoxamine (DF) for the rapid clearance of excess iron and prevention of heart disease in thalassaemia. Abstract Book. Proceedings of the 15th ICOC, April 22-26, 2005, Taichung, Taiwan. 2005; 74-75.
19. Cappelini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Prac Res Clin Haematol 2005; 18(2):289-298.
20. Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005; 366(9488):804.